loading
Adverum Biotechnologies Inc stock is traded at $2.97, with a volume of 128.00K. It is up +1.37% in the last 24 hours and up +11.24% over the past month. Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$2.93
Open:
$2.95
24h Volume:
128.00K
Relative Volume:
0.63
Market Cap:
$62.32M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.4942
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
+3.85%
1M Performance:
+11.24%
6M Performance:
-24.62%
1Y Performance:
-57.87%
1-Day Range:
Value
$2.785
$3.047
1-Week Range:
Value
$2.71
$3.047
52-Week Range:
Value
$1.78
$8.56

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
Name
Adverum Biotechnologies Inc
Name
Phone
(650) 649-1004
Name
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Name
Employee
155
Name
Twitter
@adverumbio
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ADVM's Discussions on Twitter

Compare ADVM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADVM
Adverum Biotechnologies Inc
2.97 61.48M 0 -94.11M -86.06M -6.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-25-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Jul-07-22 Upgrade Truist Hold → Buy
Jul-23-21 Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21 Downgrade SVB Leerink Outperform → Mkt Perform
Apr-29-21 Downgrade Chardan Capital Markets Buy → Neutral
Apr-29-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Apr-29-21 Downgrade Truist Buy → Hold
Dec-16-20 Initiated UBS Neutral
Nov-12-20 Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20 Downgrade Raymond James Mkt Perform → Underperform
May-13-20 Initiated RBC Capital Mkts Outperform
May-05-20 Upgrade SunTrust Hold → Buy
Apr-28-20 Initiated Goldman Buy
Mar-16-20 Initiated SVB Leerink Outperform
Feb-10-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Feb-10-20 Upgrade Chardan Capital Markets Neutral → Buy
Oct-15-19 Reiterated Chardan Capital Markets Neutral
Sep-13-19 Reiterated Chardan Capital Markets Neutral
Jun-14-19 Resumed Raymond James Mkt Perform
Nov-02-18 Downgrade Raymond James Outperform → Mkt Perform
Nov-02-18 Downgrade SunTrust Buy → Hold
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-30-18 Initiated SunTrust Buy
Feb-15-18 Resumed Piper Jaffray Overweight
Oct-12-17 Initiated Raymond James Outperform
View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

pulisher
Aug 18, 2025

Chartists Watching For Breakout in Adverum Biotechnologies Inc.July 2025 Action & Daily Stock Trend Watchlist - newsyoung.net

Aug 18, 2025
pulisher
Aug 18, 2025

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.

Aug 18, 2025
pulisher
Aug 16, 2025

Real time alert setup for Adverum Biotechnologies Inc. performanceStock Surge & Reliable Momentum Entry Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Full technical analysis of Adverum Biotechnologies Inc. stockJuly 2025 Selloffs & Free High Return Stock Watch Alerts - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Technical analysis overview for Adverum Biotechnologies Inc. stockWeekly Stock Summary & Smart Money Movement Alerts - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Reversal indicators forming on Adverum Biotechnologies Inc. stock2025 Volatility Report & Fast Entry High Yield Tips - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Chardan Capital Keeps Buy Rating for ADVM with $33 Price Target - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Adverum Biotechnologies (NASDAQ:ADVM) Receives “Buy” Rating from Chardan Capital - Defense World

Aug 14, 2025
pulisher
Aug 14, 2025

What makes Adverum Biotechnologies Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

How to build a dashboard for Adverum Biotechnologies Inc. stockGDP Growth & Verified Trade Idea Suggestions - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

Chardan Capital Keeps Buy Rating on Adverum, Raises PT to $33 - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Using data tools to time your Adverum Biotechnologies Inc. exit2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Adverum Biotechnologies shares rise 6.88% premarket after reporting a loss of $49.2 million in Q2 2025. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Adverum Biotechnologies: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

How high can Adverum Biotechnologies Inc. stock price go in 20252025 Volatility Report & Long-Term Growth Stock Strategies - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Adverum Biotechnologies Faces Financial Hurdles Amid Gene Therapy Development - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies shares fall 8.91% after-hours after reporting a larger-than-expected Q2 loss. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies shares rise 4.86% after-hours despite reporting a $49.2 million loss in Q2. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies Q2: ARTEMIS Phase 3 enrollment exceeds expectations. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies Q2 GAAP EPS Misses Expectations, Cash Holdings Down to $44.4M - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies Reports Q2 2025 Financial Results, Exceeds ARTEMIS Enrollment Expectations, Announces $10M Private Placement with Frazier Life Sciences. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies, Inc. SEC 10-Q Report - TradingView

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28) - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum Biotechnologies Q2: ARTEMIS Phase 3 Enrollment Exceeds Expectations, $10mln Private Placement - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Adverum's One-and-Done Eye Treatment Attracts Record Trial Enrollment as 50% of Specialists Back Gene Therapy - Stock Titan

Aug 12, 2025
pulisher
Aug 12, 2025

Technical signs of recovery in Adverum Biotechnologies Inc.3-Year Equity Summary With Setup Insights - Newser

Aug 12, 2025
pulisher
Aug 11, 2025

Published on: 2025-08-11 03:29:27 - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Is Adverum Biotechnologies Inc. stock bottoming outReal Trader Watchlist with Entry Targets - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

What to do if you’re stuck in Adverum Biotechnologies Inc.High Confidence Strategy with Trend Alignment - Newser

Aug 11, 2025
pulisher
Aug 09, 2025

Adverum Biotechnologies Inc. stock prediction for this weekChart Driven Opportunity Scanner with Alerts - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Is Adverum Biotechnologies Inc. a candidate for recovery playMarket Opportunity Tracker for Swing Traders - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Adverum Biotechnologies Inc expected to post a loss of $2.25 a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Adverum Biotechnologies shares fall 2.38% intraday after executives to participate in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire

Aug 06, 2025
pulisher
Aug 06, 2025

Adverum Leadership to Share Latest Ophthalmology Insights at H.C. Wainwright Conference - Stock Titan

Aug 06, 2025

Adverum Biotechnologies Inc Stock (ADVM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Adverum Biotechnologies Inc Stock (ADVM) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Seyedkazemi Setareh
CHIEF DEVELOPMENT OFFICER
May 15 '25
Sale
2.00
924
1,848
13,768
Fischer Laurent
CEO, PRESIDENT AND DIRECTOR
May 15 '25
Sale
2.00
9,126
18,252
87,488
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 27 '25
Buy
5.19
16,593
86,089
141,800
Leonard Braden Michael
10% Owner
Apr 22 '25
Buy
3.00
300,000
900,000
3,057,526
Leonard Braden Michael
10% Owner
Apr 23 '25
Buy
2.98
50,000
148,950
191,800
Leonard Braden Michael
10% Owner
Mar 31 '25
Buy
4.38
19,566
85,668
2,742,317
Leonard Braden Michael
10% Owner
Apr 02 '25
Buy
4.04
15,209
61,408
2,757,526
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 18 '25
Buy
4.69
62,341
292,418
2,667,161
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):